Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Overview - Syndax Pharmaceuticals is a commercial-stage organization focused on oncology, with two leading products targeting acute leukemia, specifically KMT2A and NPM1 acute leukemia, which together cover approximately 50% of the market for acute leukemia [3][4] Product Details - The company is a leader in the menin inhibitor class of drugs, being first to market and possessing a best-in-class profile [4] - The drug was launched in late 2024 and experienced significant sales growth throughout the last year, continuing into the current year [4]